Patrick Daly
Patrick Daly is an Assistant Editor at AMC Media Group.
Articles by Patrick Daly
Cilta-cel improved survival outcomes compared with standard care in patients with lenalidomide-refractory multiple myeloma.
Carfilzomib improved PFS versus bortezomib in induction therapy regimens with lenalidomide and dexamethasone in MM.
Lenalidomide-associated ALL was seen in patients with MM, but discontinuation alone led to regression of clonal populations.
Patients with CLL who progressed after ibrutinib and venetoclax did not show mutations linked with treatment resistance.
Nemtabrutinib induced a response in 75% of patients with CLL, and investigators established a phase II dose of 65 mg daily.
A time-limited regimen including a PI3K inhibitor was safe and highly effective in patients with relapsed or refractory CLL.
Patients with relapsed or refractory multiple myeloma sustained durable remissions after switching to biweekly teclistamab.
Mosunetuzumab plus polatuzumab vedotin achieved high CR rates in relapsed or refractory MCL with prior BTKi treatment.
Interspersing cytarabine in R-CHOP induction therapy did not yield significant improvements in elderly patients with MCL.
BOVen induced high rates of response and MRD-negativity among patients with untreated MCL with TP53 mutations.
Elranatamab was effective and well-tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma.
There were no significant differences in response rates with pegylated interferon-alpha versus hydroxyurea in MPN treatment.
Axi-cel showed promising efficacy and safety in patients with relapsed or refractory indolent non-Hodgkin lymphomas.
Two surrogate markers predicted treatment effect on eight-year progression-free survival in patients with extranodal MZL.
Primary myelofibrosis developed secondary neoplasms earlier and at higher rates versus other myeloproliferative neoplasms.
Essential thrombocythemia with CALR mutations had a higher risk of progression to myelofibrosis compared with JAK2 mutations.
A deep learning-based pathomics approach had potential in estimating bone marrow cellularity in patients with MPNs.
MPNs were not the primary cause of strokes in veterans, though researchers found they were strongly associated.
Patients with polycythemia vera developed secondary malignancies at a higher rate versus other myeloproliferative neoplasms.
BCL-2 protein hyperphosphorylation underlies both intrinsic and acquired resistance to venetoclax in CLL, study finds.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.